A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Combination Vaccine Candidates in Older Adults
Latest Information Update: 26 Nov 2024
At a glance
- Drugs BNT 161 (Primary) ; Respiratory syncytial virus vaccine Pfizer (Primary)
- Indications Influenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
Most Recent Events
- 10 Oct 2023 Status changed from active, no longer recruiting to completed.
- 15 Sep 2023 Planned End Date changed from 16 Sep 2023 to 28 Sep 2023.
- 15 Sep 2023 Planned primary completion date changed from 16 Sep 2023 to 28 Sep 2023.